Summary
Graves’ ophthalmopathy (GO) is the most common extra-thyroidal manifestation of Graves’ disease. The treatment options for GO are high-dose glucocorticoids, selenium, rituximab, cyclosporine, orbital radiotherapy (RT), and surgery. A 43-year-old male patient was referred to our clinic with complaints of severe bilateral proptosis, diplopia, and orbital pain at both globes for 1 year. Pretreatment magnetic resonance imaging revealed bilateral proptosis, the expansion of bilateral optic nerves sheath, the increase of right medial muscle thickness, and a mass at the right eyehole. Patient was treated with 1 Gy per fraction per week with a total dose of 10 Gy over 10 weeks with adoptive intensity-modulated radiotherapy technique. During RT at 3rd and 6th weeks, a moderate shrinkage of the lesions was observed. The patient has been disease free, has had no complaints for 36 months, and has not required any surgical intervention. No late side effects such as retinopathy or cataract were observed. Orbital RT with innovative techniques may be considered as an initial local treatment for GO. With adoptive protracted low dose RT, a good clinical and radiological response could be seen without increasing early and late reactions.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Abboud M, Arabi A, Salti I, et al. Outcome of thyroid associated ophthalmopathy treated by radiation therapy. Radiat Oncol. 2011;6:46.
Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol Phys. 2012;82(1):117–23.
Kouloulias V, Kouvaris J, Zygogianni A, et al. Efficacy and toxicity of radiotherapy for Graves’ ophthalmopathy: the University of Athens experience. Head Neck Oncol. 2013;5(2):12.
Li Yim JF, Sandinha T, Kerr JM, et al. Low dose orbital radiotherapy for thyroid eye disease. Orbit. 2011;30(6):269–74.
Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–90.
Kim JM, LaBree L, Levin L, et al. The relation of Graves’ ophthalmopathy to circulating thyroid hormone status. Br J Ophthalmol. 2004;88(1):72–4.
Kozaki A, Inoue R, Komoto N, et al. Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis Sci. 2010;87(3):200–4.
Marcocci C, Marino M. Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):325–37.
Cardoso CC, Giordani AJ, Wolosker AM, et al. Protracted hypofractionated radiotherapy for Graves’ ophthalmopathy: a pilot study of clinical and radiologic response. Int J Radiat Oncol Biol Phys. 2012;82(3):1285–91.
Dolman PJ, Rath S. Orbital radiotherapy for thyroid eye disease. Curr Opin Ophthalmol. 2012;23(5):427–32.
Nguyen NP, Krafft SP, Vos P, et al. Feasibility of tomotherapy for Graves’ ophthalmopathy: dosimetry comparison with conventional radiotherapy. Strahlenther Onkol. 2011;187(9):568–74.
Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2006;91(12):4817–24.
Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89(12):5910–5.
Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326(26):1733–8.
Hiromatsu Y, Eguchi H, Tani J, et al. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med. 2014;53(5):353–60.
Micke O, Seegenschmiedt MH, German Working Group on Radiotherapy in G. Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany. Int J Radiat Oncol Biol Phys. 2002;52(2):496–513.
Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18(3):333–46.
Kahaly GJ, Rosler HP, Pitz S, et al. Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab. 2000;85(1):102–8.
Conflict of interest
Ozan Cem Guler, Cem Onal, and Gungor Arslan delcare that there are no actual or potential conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guler, O., Onal, C. & Arslan, G. Graves’ ophthalmopathy treated with protracted hypofractionated low-dose adaptive radiotherapy: case report and review of the literature. Wien Klin Wochenschr 128, 299–303 (2016). https://doi.org/10.1007/s00508-015-0870-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-015-0870-z